Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)

A. S. Paller*, M. M.B. Seyger, G. Alejandro Magariños, J. Bagel, A. Pinter, J. Cather, S. Keller, C. Rodriguez Capriles, R. Gontijo Lima, G. Gallo, C. A. Little, E. Edson-Heredia, L. Li, W. Xu, K. Papp

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)'. Together they form a unique fingerprint.

Medicine & Life Sciences